HSP90 alpha Antibody: FITC

HSP90 alpha Antibody: FITC

• Background: HSP90 is an abundantly and ubiquitously expressed heat shock protein. It is understood to exist in two principal forms α and β, which share 85% sequence amino acid homology. The two isoforms of HSP90, are expressed in the cytosolic compartment (1). Despite the similarities, HSP90α exists predominantly as a homodimer while HSP90β exists mainly as a monomer (2). From a functional perspective, HSP90 participates in the folding, assembly, maturation, and stabilization of specific proteins as an integral component of a chaperone complex (3-6). Furthermore, HSP90 is highly conserved between species; having 60% and 78% amino acid similarity between mammalian and the corresponding yeast and Drosophila proteins, respectively. HSP90 is a highly conserved and essential stress protein that is expressed in all eukaryotic cells. Despite it's label of being a heat-shock protein, HSP90 is one of the most highly expressed proteins in unstressed cells (1–2% of cytosolic protein). It carries out a number of housekeeping functions – including controlling the activity, turnover, and trafficking of a variety of proteins. Most of the HSP90-regulated proteins that have been discovered to date are involved in cell signaling (7-8). The number of proteins now know to interact with HSP90 is about 100. Target proteins include the kinases v-Src, Wee1, and c-Raf, transcriptional regulators such as p53 and steroid receptors, and the polymerases of the hepatitis B virus and telomerase (5). When bound to ATP, HSP90 interacts with co-chaperones Cdc37, p23, and an assortment of immunophilin-like proteins, forming a complex that stabilizes and protects target proteins from proteasomal degradation. In most cases, HSP90-interacting proteins have been shown to co-precipitate with HSP90 when carrying out immunoadsorption studies, and to exist in cytosolic heterocomplexes with it. In a number of cases, variations in HSP90 expression or HSP90 mutation has been shown to degrade signaling function via the protein or to impair a specific function of the protein (such as steroid binding, kinase activity) in vivo. Ansamycin antibiotics, such as geldanamycin and radicicol, inhibit HSP90 function (9). For more information visit our HSP90 Scientific Resource Guide at http://www.HSP90.ca.
• Description: Mouse Anti-Human HSP90 alpha Monoclonal IgG2a
• Specifications: Detects 90kDa. This is an alpha-specific product.
• Product Name Alternative: HSP86 Antibody, HSP89A Antibody, HSP90A Antibody, HSP90AA1 Antibody, HSP90Alpha Antibody, HSPC1 Antibody, HSPCA Antibody, HSPCAL3 Antibody
• Synonyms: HSP90 alpha Antibody, Clone Hyb-K41009: FITC
• CAS Number: 9007-83-4
• UNSPSC: 12352203
• Gene ID: 3320
• Swiss Prot: P07900
• Accession Number: NP_001017963.2
• Cellular Locus: Cytoplasm | Melanosome
• Host: Mouse
• Species Reactivity: Human, Mouse, Rat
• Immunogen: Recombinant human HSP90alpha; Specificity mapped to amino acids 604-731
• Target: HSP90 alpha
• Clonality: Monoclonal
• Isotype: IgG2a
• Clone: Hyb-K41009
• Conjugation: FITC
• Validated Applications: IHC, ICC/IF
• Purification: Protein G Purified
• Limit Of Detection: 1 µg/ml of SMC-108 was sufficient for detection of HSP90alpha in 20 µg of heat shocked HeLa cell lysate by colorimetric immunoblot analysis using Goat anti-mouse IgG:HRP as the secondary antibody.
• Concentration: 1 mg/ml
• Dilution: WB (1:1000), IHC (1:5000); optimal dilutions for assays should be determined by the user.
• Weight: 0.1
• Buffer: 640.91mM DMSO, 136.36mM Ethanolamine, and 9.09mM Sodium Bicarbonate in 90.9% PBS
• Precautions: Not for use in humans. Not for use in diagnostics or therapeutics. For in vitro research use only.
• References & Citations: 1. Nemoto, T. et al. (1997) J.Biol Chem. 272: 26179-26187. 2. Minami, Y, et al. (1991), J.Biol Chem. 266: 10099-10103. 3. Arlander SJH, et al. (2003) J Biol Chem. 278: 52572-52577. 4. Pearl H, et al. (2001) Adv Protein Chem. 59: 157-186. 5. Neckers L, et al. (2002) Trends Mol Med. 8: S55-S61. 6. Pratt W, Toft D. (2003) Exp Biol Med. 228: 111-133. 7. Pratt W, Toft D. (1997) Endocr Rev. 18: 306–360. 8. Pratt WB. (1998) Proc Soc Exptl Biol Med. 217: 420–434. 9. Whitesell L, et al. (1994) Proc Natl Acad Sci USA. 91: 8324–8328. 10. Nemoto, T. (1997) Biochem and Mol. Bio Intl. 42 (5): 881-889.